You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 5, 2019

Update on Thailand’s “Delisting” of Marijuana and Hemp from the Scope of Category 5 Narcotics

Subscribe to Updates

On Friday August 30, 2019, a Notification of the Thai Ministry of Public Health (“MOPH Notification”) was published in the Government Gazette. The MOPH Notification went into effect on August 31, 2019, one day after its publication.

This MOPH Notification outlines another Thai Government initiative in connection with the free cannabis policy, this time carving out further aspects of marijuana and hemp use from the stringent regulations under the Narcotics Act.

Marijuana is described in the MOPH Notification as plants of the cannabis genus, including all parts of a marijuana plant and the substances or chemicals found in a marijuana plant. Hemp is defined as plants falling within Cannabis sativa L. Subsp. sativa, including all parts of a hemp plant.

In fact, marijuana and hemp are not entirely “delisted” from the classification of Category 5 Narcotics as identified in the Narcotics Act. While these plants are still listed as Narcotics, the MOPH Notification serves to prescribe “exceptions”, meaning aspects and particulars of marijuana and hemp related products that are not considered Narcotics.

The new exceptions are summarized below.

For both marijuana and hemp

(1) Marijuana or hemp stalks, stem cores, and fibers are excepted, if dried. The products made of such dry parts are excepted, as well.

(2) Cannabidiol (CBD) extracted from marijuana or hemp is excepted if having at least 99% purity and no more than 0.01 percent by weight of tetrahydrocannabinol (THC).

(3) Extracts of marijuana or hemp having CBD as the main constituent and no more than 0.2% by weight of THC, which are considered “drugs” as per the Drug Act, or Herbal Products as identified in the Herbal Products Act.

For hemp only

(4) Hemp seeds or hemp seed oil, which are considered Food as identified in the Food Act.

(5) Hemp seed oil or hemp seed extracts, which are considered Cosmetics as identified in the Cosmetics Act.

In other words, hemp products according to the above descriptions may now be classified as Medicinal Drugs, Herbal Products, Food, or Cosmetics under their respective regulations. Marijuana may now be classified as Medicinal Drugs or Herbal Products only.

It should be noted that during the first five years under the MOPH Notification of August 30, 2019, the exceptions per (3) – (5) above apply only to domestic production by a licensee under the respective laws. This means the importation of products that would otherwise fall within those exceptions would still be regulated by the Narcotics Act—highlighting the Thai Government’s agenda in protecting Thai business operators.

According to the Thai Ministry of Public Health’s public conference held on September 2, 2019, the exception per (2) above for high-purity extracts (99% or higher of CBD; 0.01% or lower of THC) are intended to cover laboratory-grade standard extracts. For the (3) – (5) exceptions, the Thai FDA will later issue further rules under the Drug Act, the Herbal Products Act, the Cosmetics Act, or the Food Act to specifically accommodate the use of marijuana and hemp extracts in the respective products.

Moreover, amendments to the previous Industrial Hemp Regulation of 2016 are in the pipeline. The purpose of these amendments are to include non-public entities as parties having standing to apply for industrial hemp licenses.

Abridged Translation of the MOPH Notification

Remarks: The present MOPH Notification (2019) does not affect Items Nos. 2–4 on this list, which were prescribed by the previous MOPH Notification of 2018. Said unaffected items are:

No. 2:    Kratom (Mitragyna speciose);

No. 3:    Opium poppies (Papaver somniferum L. and Papaver bracteatum Lindl.); and

No. 4:    Psilocybin mushrooms.

Details about the above Nos. 2–4 are omitted from this update.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 31, 2024
On July 18. 2024, Vietnam’s Ministry of Health issued Circular No. 12/2024/TT-BYT promulgating National Technical Regulation QCVN 20-1:2024/BYT on the limits of contaminants for health supplements (“Circular 12”). The new national technical regulation is the very first relating to health supplements, and is expected to have a great impact on the control of health supplement quality in Vietnam. Circular 12 will take effect on August 1, 2025. Contents of Circular 12 The new circular prescribes limits of contaminants (heavy metals and microorganisms), testing samples and testing methods, management requirements, and responsibilities of entities manufacturing and trading in health supplements. Supplemented alcohol products which are declared as health supplements are notably excluded from the scope of the regulation. Transitional Provisions Health supplements which (i) have been granted a declaration registration certificate, and (ii) are manufactured before August 1, 2025, are allowed to continue to be imported, traded, and circulated until the expiry date of the product, even if it is not aligned with Circular 12, except when there is food safety warning. Declaration registration dossiers for health supplements submitted before August 1, 2025, will continue to be handled in accordance with the prevailing regulations at the time of submission. From August 1, 2025, if a health supplement with a granted declaration registration certificate has a manufacturer’s standard that does not comply with Circular 12, the party manufacturing/trading in the product must adjust the product standard to conform to Circular 12 and notify the authority of this adjustment.
Read More
June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
Read More
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU
Read More
February 14, 2024
Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA
Read More